

CURRICULUM VITAE

DATE: March 2024

NAME: Jill Marie Williams, M.D.
Maiden Name: Cocchiola

PRESENT TITLE: Professor of Psychiatry with Tenure
Director, Division of Addiction Psychiatry

OFFICE ADDRESS: 317 George Street, Suite 105
New Brunswick, NJ 08901

TELEPHONE NUMBER/
E-MAIL ADDRESS: 732-235-4341/ jill.williams@rutgers.edu

CITIZENSHIP: U.S.A.

EDUCATION:

Undergraduate

Pennsylvania State University
University Park, PA
B.S.(Major: Animal Bioscience)
8/1985-5/1989

Graduate and Professional

University of Medicine & Dentistry of New Jersey
Piscataway, NJ
M.D.
8/1989- 5/1993

POSTGRADUATE TRAINING:

Internship and Residencies

Duke University Medical Center
Durham, NC
Internship
7/1993-6/1994

Duke University Medical Center
Durham, NC
Psychiatry Residency
7/1994-6/1997

Duke University Medical Center
Durham, NC
Executive Chief Resident

7/1996-6/1997

Fellowship

UMDNJ- Robert Wood Johnson Medical School

Addiction Psychiatry Fellowship

7/1998-6/1999

ACADEMIC APPOINTMENTS:

Psychiatry Department

Rutgers-Robert Wood Johnson Medical School

Professor of Psychiatry with Tenure

7/2012-present

Psychiatry Department

Rutgers - Robert Wood Johnson Medical School

Director, Division of Addiction Psychiatry

2007-present

Psychiatry Department

Rutgers-Robert Wood Johnson Medical School

Vice Chair of Research

7/2019- 6/2022

Psychiatry Department

Rutgers-Robert Wood Johnson Medical School

Associate Professor of Psychiatry with Tenure

9/2008-7/2012

Psychiatry Department

UMDNJ-Robert Wood Johnson Medical School

Program Director, Addiction Psychiatry Fellowship Program

2007-2009

Psychiatry Department

UMDNJ-Robert Wood Johnson Medical School

Associate Director, Division of Addiction Psychiatry

2006-2007

Psychiatry Department

UMDNJ-Robert Wood Johnson Medical School

Associate Program Director, Addiction Psychiatry Fellowship Program

2006-2007

Psychiatry Department

UMDNJ-Robert Wood Johnson Medical School

Associate Professor of Psychiatry

7/2005-present

Department of Health Education and Behavioral Science
UMDNJ-School of Public Health
Associate Professor
2004-2013

Psychiatry Department
UMDNJ-Robert Wood Johnson Medical School
Director, Mental Health Tobacco Services
2002-present.

University Medical Group
UMDNJ-Robert Wood Johnson Medical School
Staff Psychiatrist
July 2001- present

Psychiatry Department
UMDNJ-Robert Wood Johnson Medical School
Assistant Professor of Psychiatry
7/1997-6/2005

VA NJ Health Care System
Consulting and Research Psychiatrist (W.O.C. status)
2001-2010

HOSPITAL APPOINTMENTS:

Psychiatry Department
Robert Wood Johnson University Hospital
Staff Psychiatrist
July 2001- present

Rutgers University Behavioral Health Care
Staff Psychiatrist
July 2001- present

OTHER EMPLOYMENT OR MAJOR VISITING APPOINTMENTS:

Medical Director
Tobacco Cessation Training and Technical Assistant Center (NYC TCTTAC)
Columbia University Center for Practice Innovation
2017-

Addictions Psychiatry Consultant
Rutgers Counseling, Alcohol and Other Drug Assistance Program
Rutgers University Counseling Center
2018-2020

Psychiatry Department Outpatient Clinic in General and Addiction Psychiatry
Robert Wood Johnson Medical School
Buprenorphine Certified Prescriber since 2011
July 2001- present

Brain Health Institute, Rutgers University
Senior Member
2016- present

Faculty Renewal Leave (Sabbatical)
Columbia University- Center for Practice Innovation
2012-2013

Rutgers Center of Alcohol and Substance Use Studies, Graduate School of
Applied and Professional Psychology
Affiliate
2003- Present

Cancer Institute of New Jersey
Member
2002-present

UMDNJ School of Public Health
2001-present

VA NJ Health Care System
Coordinator for Programs for Seriously Mentally Ill (SMI) Veterans
2000-2001

VA NJ Health Care System
Medical Director
Day Treatment Center and Psychosocial Residential Rehabilitation Treatment
Program
1998-2001

University Behavioral Health Care
Staff Psychiatrist
1997-1998

LICENSURE:

New Jersey, #25MA06547000, expires 6/30/2023

DRUG LICENSURE:

CDS LICENSE: D07185800 – expires 10/31/2023

DEA LICENSE: BW5478385 – expires 5/31/2024

CERTIFICATION:

Diplomat, American Board of Psychiatry and Neurology
March 1998-2008

Recertification, American Board of Psychiatry and Neurology
April 2008- 2018; Recertification through 2024

Addiction Psychiatry, Added Qualifications, American Board of Psychiatry and
Neurology, April 2002. Recertification through 2024

National Certificate of Tobacco Treatment Practice. Certified by NAADAC and
ATTUD, 2018. Certificate number NT0103

**MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN
PROFESSIONAL SOCIETIES:**

Member of International Editorial Board- British Journal of Psychiatry Open.
2019-2022

SAMHSA STR-TA (State Targeted Response Technical Assistance for Opioid
Crisis) NJ Lead Consultant for Prescribers. 2018- current

American Psychiatric Association
Appointed Council on Addictions- 2015, Reappointed 2017, 2019, 2022
Chairperson, Council on Addictions-2019-2021
Member, Member APA Workgroup on Tobacco Use Disorder- 2015
Chairman, 2010 Achievement Awards Committee, 62nd APA Institute on
Psychiatric Services, 2009-2010
Member since 1994

American Academy of Addiction Psychiatry (AAAP)
Member since 2008

American Society of Addiction Medicine (ASAM)
Member since 2008

New Jersey Breathes
Chairman
July 2013-November 2015

Association for the Treatment of Tobacco Use and Dependency (ATTUD)
Chair, Subcommittee on Mental Illness and Addictions
2007-2009
Member since 2005

Society for Research on Nicotine and Tobacco
Program Committee, 2012 SRNT Annual Meeting

2011-2012
Member since 2000

New Jersey Psychiatric Association
Member, Council on Professional Standards-2015
Member since 2000

Member, American Association of Community Psychiatrists

Member, New Jersey Psychiatric Association

Member, Middlesex County Mental Health Professional Advisory Committee
(PAC)

Member, New Jersey Association of Mental Health and Addiction Agencies
(NJAMHAA), Inc. Co-Occurring Disorders Committee

HONORS AND AWARDS:

Wiley Recognition. -Top Downloaded Article in the first 12 months of
publication. Educating the Community about the Opioid Epidemic and
medications for Opioid Use Disorder. Am J on Addictions. March 2024.

Distinguished Fellow
American Psychiatric Association
January 2020

Recognition of Excellence (CHOICES Program) in Wellness by the Substance
Abuse and Mental Health Services Administration's (SAMHSA's) Program to
Achieve Wellness (PAW)
July 2016

2015 Remarkable Achievement Award
NJ Psychiatric Association.
November 2015

Best Doctors
NY Magazine, NJ Monthly
2015, 2016, 2017, 2018, 2019

Silver Award, CHOICES Program
American Psychiatric Association Institute of Psychiatric Services
October 2009

Partnership Achievement Award
NJ Department of Human Services
State Hospital Tobacco Cessation Team

May 2008.

Alcohol Medical Scholars Program
(M Schuckit, Director)
August 2005- 2007

Innovation In Programming Award, CHOICES Program
Mental Health America
June 2007

Future Leaders in Psychiatry Symposium, 6th Annual
April 2004

American Psychiatric Association's Research Colloquium for Junior Investigators
Advanced Track Participant
May 2004

American Psychiatric Institute for Research and Education
Janssen Pharmaceutical Public Policy Leadership Program Fellow
2000-2001

American Psychiatric Association's Research Colloquium for Junior Investigators
May 1999

George Ginsberg-American Association of Directors of Psychiatric Residency
Training (AADPRT) Charter Fellowship
1997

N.C. Governor's Institute for Alcohol and Substance Abuse Public Policy Scholar
1995-1996

Garden State Distinguished Scholar
1985

**SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS,
COMMITTEES:**

RPIA (Risk, Prevention and Intervention for Addictions Study Section) Ad Hoc
Grant Reviewer
February 2012; June 2012

NIMH. Ad Hoc Grant Reviewer
Special Emphasis Panel / Interventions Committee for Disorders Related to
Schizophrenia, Late Life or Personality
February 2008

NIDA, Ad Hoc Grant Reviewer

Special Emphasis Panel. National Cooperative Drug Discovery Groups for the Treatment of Mood Disorders or Nicotine Addiction (NCDDG-MD/NA)
July 2004

National Institutes of Health Working Group, NCI-NIDA-NIAAA
Pharmacologic Approaches to Nicotine Addiction
October 2002

Consultant and Co-Organizer for National Initiative Advisory Panel:
Addressing Tobacco among Individuals with Mental Illness or Addiction
Robert Wood Johnson Foundation
2002- 2003

SERVICE ON MAJOR COMMITTEES:

National

Consultant, New York State Office of Mental Health, Tobacco Dependence Treatment Modules Review Committee for the Focus on Integrated Treatment (FIT) Training Systems, Center for Practice Innovations at Columbia University Department of Psychiatry, 2010-2012

Appointment, New Jersey Health Information Technology Commission, 2009-2010

Consultant, New York City Department of Mental Health & Hygiene, Public Health Detailing Program on Smoking Cessation to Mental Health Providers, 2008

Consultant, Ohio Substance Abuse Mental Illness & Supported Employment Coordinating Centers at Case (SAME- SECC), Implementation of Tobacco Dependence Treatment and Tobacco-Free Policies in Ohio's Mental Health and Alcohol and Drug Addictions Services Systems, 2007-2009.

Consultant, Ohio Prevention Foundation, 2005-2008.

Workgroup on Tobacco Use Disparities, New Jersey Comprehensive Tobacco Control Program (CTCP), 2007-2009.

Smoking Policy Committee, New Jersey Division of Mental Health Services, 2006-2009.

New Jersey Institute for Continuing Education in Tobacco, 2006-2008.

Public Policy Committee, Mental Health Association in New Jersey, 2005-2009.

Task Force on Co-Occurring Disorders, New Jersey Department of Mental Health, 2002-2004

Medical School/ University

RWJMS Compensation Trends Transparency Committee, 2021-2023

RWJMS Admissions Committee, 2018-2021

RWJMS Appointments and Promotions Committee, 2014-2020; 2023-2024

University Medical Group Executive Council, 2014-2016

RWJMS Executive Council, 2011-2012; 2016- current

RWJMS. Faculty Senate Exploratory Committee, 2007-2008.

RWJMS Student Assistance Campus Committee (SACC), 2003-2009.

Department

RWJMS Department of Psychiatry Executive Council, 2007-present

RWJMS Department of Psychiatry Research Committee, 2001-2016

RWJMS Residency Education Committee, 1997-present.

RWJMS Department of Psychiatry On-Call Committee, 2005-2012

RWJMS Addictions Training Committee, Division of Addictions, 1999-2008.

Journal Reviewer

Associate Editor. Journal of Dual Diagnosis. February 2014-2017

Associate Editor. British Journal of Psychiatry Open. 2019-2022

AdHoc Reviewer

Psychiatric Services since 1998

Schizophrenia Research since 1998

Community Mental Health Journal since 1999

American Journal on Addictions since 2001

Journal of Clinical Psychiatry since 2001

Biological Psychiatry since 2004

American Journal of Psychiatry since 2004

Nicotine & Tobacco Research since 2007

Journal of Dual Diagnosis since 2008

SERVICE ON HOSPITAL COMMITTEES:

VA NJ Health System, Champion for Implementation of VHA's Guideline for Management of Patients with Psychoses: Module on Schizophrenia, 1999-2001.
VA NJ Health Care System, Practice Guidelines Committee, 1999-2001.
VA NJ Health Care System, Pharmacy and Therapeutics Committee, 1998-2001.
VA NJ Health Care System, Process Improvement Team for Smoke-Free VA, 1998.

TEACHING RESPONSIBILITIES

Lectures or Course Directorships

Robert Wood Johnson Medical School, Twelve Month Elective for Medical Students I and II, Course Director and Lecturer: Introduction to Opioids: Addiction, Treatment and Harm Reduction . 2017-present

Robert Wood Johnson Medical School, Neuron, Brain and Behavior Course or Medical Students II, Lecturer, Biology of Addiction and Introduction to Substance Use Disorders. 2016-present

Robert Wood Johnson Medical School Psychiatry Residency Program
Course Director and Lecturer: Substance Use Disorders half-year course. 2010-present

Robert Wood Johnson Medical School, Behavioral Science Course for Medical Students II, Lecturer: Club Drugs and Hallucinogens. 2005-2011

Robert Wood Johnson Medical School, Behavioral Science Course for Medical Students II. Lecturer: Tobacco Dependence. 2005-2011

Robert Wood Johnson Medical School Psychiatry Residency Program
Course Director: Critical Review of the Literature. 2010-2016

UMDNJ-School of Public Health, Part of UMDNJ-Tobacco Dependence Program
5-Day Training to Become a Tobacco Treatment Specialist, Neurobiology of Addiction. 2002-present.

Robert Wood Johnson Medical School, Medical Students III on Psychiatry Clerkship, Clinical Introduction to Substance Abuse. 2005-2006

VA NJ Health Care System, Site Coordinator. Basic Interviewing Skills Course for second year medical students, 1999-2001.

Duke University Medical Center, Course Director and Lecturer. Chief resident's seminar in major psychopathological entities for second year medical students. 1996-1997.

Continuing Medical Educations

CME Course Director and Lecturer

Treating Tobacco Dependence in Behavioral Health Settings. A two-day training conference for Psychiatrists, Advanced Practice Nurses and Other Mental Health Professionals. UMDNJ-RWJMS. Since 2006.

CE Course Director and Lecturer

Moving Forward with a Quality Improvement Model for Addressing Tobacco in Behavioral Health Settings. Three one-day CE activities based on our comprehensive model for Implementing Mental Health Tobacco Recovery in New Jersey (MHTR-NJ). UMDNJ-RWJMS. Since 2011.

Chair of Online CME Case Study

Approaching Smoking Cessation in a Patient with Alcohol Use Disorder. CME Enterprise (www.ceasesmoking2day.com) 2010-2011.

Research Training

Pre Doctoral, Doctoral or MPH Students

Lauren Scher, PsyD	2001-2003
Francesca Abanyie, MD, MPH (Fieldwork)	2004-2006
Rita Oommen, Pharm D (Rutgers University)	2002-2004
Kunal Gandhi, MBBS, MPH (Fieldwork)	2004-2011
Teo-Carlo Straun, MD	2004-2006
Magdalena Galazyn, PhD	2007-2010
Supriya Kumar, MPH	2008-2011
Brooke Stipleman, PhD	2007-2008
Sarah Hill, MD	2008-2009
Heather Fischer, MPH (Fieldwork)	2011-2012
Kaitlin Reilly, MD	2011-2012
Kristine Goins, MD	2012-2013
Alexandra Kenafake, MBS (Capstone)	2014-2015
Kristy Lento Iglay, PhD (Dissertation)	2014-2015
Omowunmi Adedeji, MD	2018-2019
Ajan Sivaramamoorthy, MD	2018-2019
Ariel Tabachnik, MD	2019-2020
Muzdalifa Ayub, MPH (Fieldwork)	2019-2020
Rahul Ramasubramani, MD	2019-2021
Nicholas Lozano, MPH (Fieldwork)	2019-2020
Ariana Gover-Chamlou, MD (Distinction Research)	2020-2021
Aderike Adesanya, MPH (Fieldwork)	2020-2021
George Gardner, MBS (Capstone)	2020-2021
Kelley Hamilton, MPH (Fieldwork)	2022-2023
Halie Pratt MPH (Fieldwork)	2022-2023

Rutgers Undergraduate Students

Kiran N Ali, BA (Cook Scholar Honors Thesis) 2018-2019

CLINICAL RESPONSIBILITIES:

Rutgers Health /University Medical Group, Addictions Psychiatrist, 2001-present

VA NJ Health Care System, Medical Director, Day Treatment Center and Psychosocial Residential Program, 1998-2001

UMDNJ-University Behavioral Health Care, Staff Psychiatrist. Division of Extended Care, 1997-1998

GRANT SUPPORT:

Principal Investigator

Train the Trainer Medication Assisted Treatment Education for Rutgers Students. NJ Department of Human Services, Division of Mental Health and Addiction Services. \$250,000. 2020-2022; Renewed 2022-2024

Using Peer Counselors to Address Tobacco among Mental Health Consumers. NJ Division of Mental Health Services, \$154,311. Renewed Annually since 2009.

Cancer Prevention Needs Assessment for Behavioral Health. Funded by Screen NJ (CINJ). \$30,000. 2020-2021. Williams, PI and Kline Co-I

Train the Trainer Medication Assisted Treatment Education for Rutgers Students. NJ Department of Human Services, Division of Mental Health and Addiction Services. \$85,000. 2019-2020

Pfizer Inc. Continuation and Analysis of Enhanced Tobacco Use Measures and Intensive Training in New York. AWD00003986. Type: Grant, \$50,000. 2018-2019.

Medication Assisted Treatment Outreach Program (MATOP). NJ Department of Human Services, Division of Mental Health and Addiction Services. 2015-2018. \$375,000.

Pfizer Inc. Implementation of Enhanced Tobacco Use Measures and Intensive Training in New York. Type: CME Grant 16968713, \$150,000. 2015-2017.

American Board of Psychiatry and Neurology. Online Residency Training in Tobacco Use Disorders. \$100,000. 2015-2016

NJ Department of Human Services, Division of Mental Health and Addiction Services. Tobacco Training and Technical Support for NJ Regional Prevention Coalitions. \$80,000. Term 2014-2018

Treating Tobacco in Behavioral Health Settings, 2 Day CME/ CE Course. Several contracts to conduct this evidence-based training out of state in New York, Georgia, Minnesota, Texas, North Dakota. 2013-2017

National Council for Behavioral Health. Webinar Series for PBHCI Grantees on Treating Tobacco. \$13,000. 2014.

Pfizer Inc. , A Statewide Implementation of the Treating Tobacco in Mental Health Settings Training. Type: CME Grant 044668, \$100,000. 2013-2014.

Tobacco Free Residential Addiction Programs. NJ Department of Human Services, Division of Mental Health and Addiction Services, \$600,000. Term 2011-2014.

National Institute of Drug Abuse, Double-Blind, Placebo-Controlled Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia, Type: R01-DA024640-01A1, \$390,000. Term 7/15/2009 to 8/14/2011.

Pfizer Inc., Treating Tobacco Dependence in Mental Health Settings, Type: CME Grant 033260, \$20,000. Term 1/1/2011 to 12/31/2011.

Pfizer Inc., A Comprehensive Training Model for Training Tobacco Dependence in Mental Health Settings. Type: CME Grant 033722, \$55,000. Term 1/1/2011 to 12/31/2011.

Cancer Institute of New Jersey, The effect of menthol on nicotine levels and metabolites in African American cigarette smokers. Type: 2009 Research Development Award, \$95,000; Term 2009-2010

Pfizer Inc. Phase 3B 12-Week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder, \$353,368. Term 2008-2009

National Institute of Mental Health, Nicotine Intake in Schizophrenia, R01-MH076672-01A1, \$1,412,916; Term 2006-2010.

National Institute of Mental Health, Carcinogen biomarkers in smokers with schizophrenia (supplement to Nicotine Intake in Smokers With Schizophrenia) Grant; R01-MH076672-01A1, \$127,563, Term 2008-2010.

Pfizer, Inc., Unrestricted Educational Grant, Training Psychiatrists and Psychiatric Advanced Practice Nurses to Treat Tobacco Dependence., \$20,000. Term 2009.

National Institute on Drug Abuse/VA multi-center collaborative study, Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS)

as an Aid for Smoking Cessation. NIDA/VA CSP-1022. Term 2007-2009, \$460,875.

NJ Division of Mental Health Services, Using Peer Counselors to Address Tobacco among Mental Health Consumers. \$ 68,328. Term 2008-2009

National Institute on Drug Abuse Mentored Patient-Oriented Research Career Development Award. Nicotine Dependence Treatment in Psychiatric Comorbidity #K23-DA14009-01, \$811,145, Term 2001-2006.

American Legacy Foundation, Small Innovative Grant Program, Using Peer Counselors to Address Tobacco among Mental Health Consumers, \$100,000, Term 2005-2007

American Legacy Foundation, Small Innovative Grant Program, Training Psychiatrists and Psychiatric Advanced Practice Nurses to Treat Tobacco Dependence, \$40,000, Term 2006-2007

Pfizer, Inc. Unrestricted Educational Grant, Training Psychiatrists and Psychiatric Advanced Practice Nurses to Treat Tobacco Dependence, \$10,000. Term 2006-2007.

NJ Division of Mental Health Services, Using Peer Counselors to Address Tobacco among Mental Health Consumers, \$50,000. Term 2007-2008

NJ Division of Mental Health Services, Using Peer Counselors to Address Tobacco among Mental Health Consumers, \$50,000, Term 2006-2007

Cancer Institute of New Jersey, Using Peer Counselors to Address Tobacco among Mental Health Consumers, \$ 38,875, Term 2006-2007

N.C. Governor's Institute on Alcohol and Substance Abuse, Inc., Dual Diagnosis Patients in a State Facility: A Comparison of Staff Attitudes with Actual Treatment Practices, \$5000, Term 1995-1996.

As Co-Investigator

NYC Department of Health and Mental Hygiene (DOHMH). NYC Behavioral Health Tobacco Cessation Training and Implementation Center Proposal (Covell N-PI; Columbia/ RFMH) \$666,000 Term: 5/1/17- 2/31/22; Renewed 2022-2024

National Institute on Drug Abuse. Persistence Targeted Smoking Cessation in Schizophrenia (PTSC-S; Steinberg ML- PI). R21DA041163-01 (R21/R33) 2016 – 2021

Laura and John Arnold Foundation. Emergency Department Peer Recovery Support for Opioid Overdose Survivors. (Cooperman- PI). Term 3/1/18-2/28/22

NJ Department of Mental Health and Addiction Services. Opioid Overdose Prevention Network (Cooperman-PI). Term 9/1/16-8/31/21

National Cancer Institute. RCT of a Motivational Decision Support System for Smokers with SMI (Brunette M-PI ; Dartmouth). 1 R01 CA168778-01, \$ 895,717. 9/1/2013-8/31/2016.

National Institute on Drug Abuse. Persistence Targeted Smoking Cessation (Steinberg ML-PI). 1R34DA030652-01A1, \$715,663. 9/30/11 – 8/31/14.

National Institute of Mental Health, Perceptual organization dysfunction as a biomarker of schizophrenia (Silverstein- PI), R01MH093439-01, Term: 4/1/11-3/31/16

National Institute of Drug Abuse, Developing and Smoking Cessation for Methadone Maintained Smokers (Cooperman- PI), 1K23DA025049-01A1, \$ 816,724. Term: 2009-2014.

Pfizer 2010 GRAND Award. Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit (Steinberg ML-PI), \$200,000. 12/1/2010 – 11/30/2012.

National Institute on Alcohol Abuse and Alcoholism, Testing CBT Models and Change Mechanisms for Alcohol Dependent Women (Epstein- PI), R01 AA017163-01. Term 9/2008 – 8/2013.

National Institute of Drug Abuse, Treatment of Addiction to Nicotine in Schizophrenia. (Ziedonis- PI). R01 DA015537 \$1,513,905.. Term 2003-2007.

National Institute of Drug Abuse, Treatment Issues for Smokers with Schizophrenia (Steinberg ML- PI), K23 DA018203-02, \$707,676 Term: 2004-2009

NJ Department of Health & Senior Services, Tobacco Dependence Program (Foulds-PI). Term: 7/1/00- 6/30/09.

Robert Wood Johnson Foundation, Substance Abuse Policy Research Program, Tobacco Use among the Mentally Ill: an Overlooked Tobacco Control Issue (Delnevo PI) 1/1/2006 – 6/30/2007.

National Institute of Mental Health Tobacco use in people with mental disorders: an overlooked tobacco control issue (Delnevo PI). R03MH077273-01A1 , Term 1/1/2007- 12/31/2007.

NJ Department of Health and Human Services, Division of Mental Health,

PUBLICATIONS:

Refereed Original Article in Journal

<https://www.ncbi.nlm.nih.gov/myncbi/16QSvwg6htMkn/bibliography/public/>

1. Baker AL, McCarter K, Turner A, Segan C, Castle D, Brophy L, Borland R, Kelly PJ, Bonevski B, Baird D, Filia S, Attia J, Szwec S, Palazzi K, Sarah L, White SL, **Williams JM**, Wrobel AL, Ireland A, Saxby K, Ghijben P, Petrie D, Sweeney R. Quitlink: Outcomes of a randomized controlled trial of peer researcher facilitated referral to a tailored quitline tobacco treatment for people receiving mental health services. *Australian and New Zealand Journal of Psychiatry*. Accepted, in press.
2. Kline A, **Williams JM**, Steinberg ML, Mattern D, Chesin M, Borys S, Chaguturu V. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone. *J Subst Use Addict Treat*. 2023 Jun;149:209028. doi: 10.1016/j.josat.2023.209028. Epub 2023 Mar 31. PMID: 37003539
3. Rosen RL, Ramasubramani RS, Benowitz NL, Gandhi KK, **Williams JM**. Caffeine Levels and Dietary Intake in Smokers with Schizophrenia and Bipolar Disorder. *Psych Research*. 2023 Jan; 319:114989. PMID: 36470161
4. McCarter K, Mckinlay M, Cocks N, Brasier C, Hayes L, Baker AL, Castle D, Borland R, Bonevski B, Segan C, Kelly PJ, Turner A, **Williams JM**, Attia J, Sweeney R, Filia S, Baird D, Brophy LM. The value of compassionate support to address smoking: A qualitative study with people who experience severe mental illness. *Frontiers in Psychiatry*. 2022 Oct 6; 13:868032. PMID: 36276321
5. **Williams JM**, Barna Bridgeman M, Laitman L. A Vulnerable Young Adult Using Cannabis for Therapeutic Purposes Despite Emerging Psychosis. *Psychiatry Research Case Reports*. 1 (2022)100037.
6. Young WJ, Delnevo CD, Singh B, Steinberg ML, **Williams JM**, Steinberg MB. Tobacco Treatment Knowledge and Practices Among US Psychiatrists. *Community Ment Health J*. 2022 Jun 29. doi: 10.1007/s10597-022-00997-9. PMID: 35768703
7. **Williams JM**, Syed MA, Adesanya A, Gardner G, Chaguturu V and Coppola KM. Educating the Community about the Opioid Epidemic and Medications for Opioid Use Disorder. *J Addict* 2022 Sep;31(5):433-440. PMID:35411688
8. Baker AL, McCarter K, Brophy L, Castel D, Kelly PJ, Cocks N, McKinlay M, Brasier C, Borland R, Bonevski B, Segan C, Baird D, Turner A, **Williams JM**, Forbes E, Hayes L, Attia J, Lambkin D, Barker D and Sweeney R. Adapting peer

researcher-facilitated strategies to recruit people receiving mental health services to a tobacco treatment trial. *Frontiers in Psychiatry* 2022 May 26; 13:869169. PMID: 35722563

9. Sheffer CE, **Williams JM**, Erwin DO, Smith PH, Carl E, Ostroff JS. Tobacco-Related Disparities Viewed through the Lens of Intersectionality. *Nicotine Tob Res.* 2022 Feb 1;24(2):285-288. PMID: 34555170.
10. Covell NH, Foster F, Lipton N, Kingman E, Aquila S and **Williams JM**. Using a Self- Evaluation Tool for Behavioral Health Programs to Support Implementing Treatment for Tobacco Use Disorder. *Community Mental Health Journal.* 2022 May; 58(4):812-820. PMID: 34518927
11. Goodwin RD, Moeller SJ, Zhu J, Yarden J, Ganzhorn S, **Williams JM**. The potential role of cocaine and heroin co-use in the opioid epidemic in the United States. *Addict Behav.* 2021 Feb;113:106680. doi: 10.1016/j.addbeh.2020.106680. Epub 2020 Sep 24. PMID: 33022537
12. Steinberg ML, Billingsley BB, Rosen RL, Epstein EE, Lu S-E, **Williams JM**. Persistence Targeted Smoking Cessation for Smokers with Schizophrenia or Schizoaffective Disorder: A Feasibility Study. Accepted, In press, *Journal of Smoking Cessation*.
13. Kline A, Mattern D, Cooperman N, **Williams JM**, Dooley-Budsock P, Foglia R, Borys S. Opioid overdose in the age of fentanyl: Risk factor differences among subpopulations of overdose survivors. *Int J Drug Policy.* 2021 Apr;90:103051. doi: 10.1016/j.drugpo.2020.103051. Epub 2020 Dec 11. PMID: 33321284
14. Zern A, Seserman M, Dacus H, Wallace B, Friedlander S, Manseau M, Smalling MS, Smith TE, **Williams JM**, Compton MT. Screening and Treatment of Tobacco Use Disorder in Mental Health Clinics in New York State: Current Status and Potential Next Steps. *Community Ment Health J.* 2021 Aug;57(6):1023-1031. doi: 10.1007/s10597-020-00726-0. Epub 2020 Oct 20. PMID: 33083939
15. Bold KW, Rosen RL, Steinberg ML, Epstein EE, McCrady BS, **Williams JM**. Smoking characteristics and alcohol use among women in treatment for alcohol use disorder. *Addict Behav.* 2020 Feb;101:106137. Epub 2019 Oct 4.
16. Kline A, Mattern D, Cooperman N, Dooley-Budsock P, **Williams JM** and Borys S. "A Blessing and a Curse:" Opioid Users' Perspectives on Naloxone and the Epidemic of Opioid Overdose. *Subst Use Misuse* 2020;55(8):1280-1287. doi: 10.1080/10826084.2020.1735437. Epub 2020 Mar 17.

17. Brunette MF, Ferron JC, McGurk SR, **Williams JM**, Harrington A, Devitt T, Xie H. Brief, Web-Based Interventions to Motivate Smokers With Schizophrenia: Randomized Trial. *JMIR Ment Health*. 2020 Feb 8;7(2):e16524.
18. Steinberg ML, Billingsley B, Rosen RL, Epstein EE, Lu SE, **Williams JM**. A novel intervention increases task persistence in smokers with schizophrenia: A proof of concept study. *Schizophr Res*. 2020 Jan;215:453-454.
19. **Williams JM**, Steinberg ML, Wang H, Chaguturu V, Poulsen R, Tobia A, Palmeri B. Practice Change after Training Psychiatry Residents in Tobacco Use Disorder. *Psychiatr Serv*. 2019 Nov 6;:appips201900272. doi: 10.1176/appi.ps.201900272.
20. Yingst JM, Foulds J, Veldheer S, Hrabovsky S, Trushin N, Eissenberg TT, **Williams J**, Richie JP, Nichols TT, Wilson SJ, Hobkirk AL. Nicotine absorption during electronic cigarette use among regular users. *PLoS ONE* 2019; 14(7): e0220300
21. Whitton AE, Green AI, Pizzagalli DA, Roth RM, **Williams JM**, Brunette MF. Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia. *Schizophr Bull*. 2019 Oct 24;45(6):1300-1308.
22. Bold, K.W., Rosen, R.L., Steinberg, M.L., Epstein, E.E., McCrady, B.S., **Williams, J.M.** Smoking characteristics and alcohol use among women in treatment for alcohol use disorder. *Addict Behav*. 2019 Oct 4;101:106137. doi: 10.1016/j.addbeh.2019.106137.
23. Sweeney R, Moodie M, Baker AL, Borland R, Castle D, Segan C, Turner A, Attia J, Kelly PJ, Brophy L, Bonevski B, **Williams JM**, Baird D, White SL, McCarter K. Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness. *Front Psychiatry*. 2019 Sep 3;10:618. doi: 10.3389/fpsyt.2019.00618.
24. **Williams JM**, Poulsen R, Chaguturu V, Tobia A and Palmeri B. Evaluation of an Online Residency Training in Tobacco Use Disorder. *American Journal on Addictions*. 2019 Jul; 28(4):277-284. DOI: 10.1111/ajad.12885
25. Brunette M, **Williams J** and Ferron J. Digital Therapeutics for Tobacco Use Disorder in People with Serious Mental health Conditions. *Schizophrenia Bulletin*, 2019; Vol 45, Supplement 2, April 2019. S95-96
26. Whitton AE, Green AI, Pizzagalli DA, Roth RM, **Williams JM**, Brunette MF. Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia. *Schizophr Bull*. 2019 Jan 22;. doi: 10.1093/schbul/sby185. PubMed PMID: 30690638.

27. Yingst JM, Foulds J, Veldheer S, Hrabovsky S, Trushin N, Eissenberg TT, **Williams J**, Richie JP, Nichols TT, Wilson SJ, Hobkirk AL. Nicotine absorption during electronic cigarette use among regular users. *PLoS One*. 2019 Jul 25;14(7):e0220300.PMID: 31344110
28. Baker AL, Borland R, Bonevski B, Segan C, Turner A, Brophy L, McCarter K, Kelly PJ, **Williams JM**, Baird D, Attia J, Sweeney R, White SL, Filia S, Castle D. "Quitlink"-A Randomized Controlled Trial of Peer Worker Facilitated Quitline Support for Smokers Receiving Mental Health Services: Study Protocol. *Front Psychiatry*. 2019;10:124. doi: 10.3389/fpsy.2019.00124.
29. Cooperman NA, Rizvi SL., Hughes, CD, **Williams, JM**. Field test of a dialectical behavior therapy skills training-based intervention for smoking cessation and opioid relapse prevention in methadone treatment. *Journal of Dual Diagnosis*, 2019 Jan 15:1-7. doi: 10.1080/15504263.2018.1548719.
30. Steinberg ML, Lu S-E, **Williams JM**. Varenicline for smoking reduction in smokers not yet ready to quit: A double-blind, proof of concept randomized clinical trial. *Addictive Behaviors*,. 2018 Sep;84:20-26. doi: 10.1016/j.addbeh.2018.03.026. Epub 2018 Mar 26.
31. **Williams JM**. Will removal of black box warning get psychiatrists to move on tobacco? *Am J Addict*. 2018 Jan;27(1):40-41. doi: 10.1111/ajad.12669. PMID: 29283491z
32. Cooperman NA, Lu, S. Richter KP, Bernstein SL, **Williams JM**. Pilot study of a tailored smoking cessation intervention for individuals in treatment for opioid dependence. *Nicotine Tob Res*. 2017 Aug 30. doi: 10.1093/ntr/ntx189.
33. Baker AL, Richmond R, Kay-Lambkin FJ, Filia SL, Castle D, **Williams JM**, Lewin TJ, Clark V, Callister R, Palazzi K. Randomised controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders: Outcomes to 36 months. *Aust N Z J Psychiatry*. 2018 Mar;52(3):239-252. doi: 10.1177/0004867417714336.
34. Iglay K, Santorelli ML, Hirshfield KM, **Williams JM**, Rhoads GG, Lin Y, Demissie K. The Impact of Pre-existing Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Breast Cancer Patients. *J Clinical Oncology* 2017; 35(36):4012-4018.
35. Baker AL, Richmond R, Kay-Lambkin FJ, Filia SL, Castle D, **Williams JM**, Lewin TJ, Clark V, Callister R, Palazzi K. Randomised controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders: Outcomes to 36 months. *The Australian and New Zealand journal of psychiatry*. 2017; :4867417714336.
36. Goodwin RD, Wall MM, Garey L, Zvolensky MJ, Dierker L, Galea S, Gbedemah M, Weinberger AH, **Williams JM**, Hu MC, Hasin DS. Depression among current, former, and never smokers from 2005 to 2013: The hidden role of

- disparities in depression in the ongoing tobacco epidemic. *Drug Alcohol Depend.* 2017 Jan 11. pii: S0376-8716(17)30008-X. [Epub ahead of print]
37. Baker AL, **Williams JM**. Building a Research Agenda for Reducing Smoking and Other Cardiovascular Risk Factors. *Journal of dual diagnosis.* 2017; 13(1):iii-v.
 38. Swarbrick MA, Cook JA, Razzano LA, Jonikas JA, Gao N, **Williams J**, Yudof J. Correlates of Current Smoking among Adults Served by the Public Mental Health System. *J Dual Diagn.* 2017 Apr 20:1-9. [Epub ahead of print]
 39. Segan CJ, Baker AL, Turner A, **Williams JM**. Nicotine Withdrawal, Relapse of Mental Illness, or Medication Side-Effect? Implementing a Monitoring Tool for People With Mental Illness Into Quitline Counseling. *J Dual Diagn.* 2017 Jan 9:1-7. [Epub ahead of print]
 40. Metse AP, Wiggers JH, Wye PM, Wolfenden L, Prochaska JJ, Stockings EA, **Williams JM**, Ansell K, Fehily C, Bowman JA. Smoking and Mental Illness: A Bibliometric Analysis of Research Output Over Time. *Nicotine Tob Res.* 2017 Jan;19(1):24-31.
 41. Andrews M, Baker AL, Halpin SA, Lewin TJ, Richmond R, Kay-Lambkin FJ, Folia SL, Castle D, **Williams JM**, Clark V, Callister R. Early Therapeutic Alliance, Treatment Retention, and 12-Month Outcomes in a Healthy Lifestyles Intervention for People with Psychotic Disorders. *J Nerv Ment Dis.* 2016 Dec;204(12):894-902. PMID:27575791
 42. **Williams JM**, Steinberg ML, Kenefake A and Burke M. An Argument for Change in Tobacco Treatment Options Guided by the ASAM Criteria for Patient Placement. *Journal of Addiction Medicine J Addict Med.* 2016 Jul 26. [Sep-Oct;10(5):291-9. doi: 10.1097/ PMID27466070
 43. Sankaranarayanan, A., Clark V, Baker A, Palazzi K, Lewin TJ, Richmond R., Kay-Lambkin FJ, Folia S, Castle D, **Williams JM**. 2016. Reducing smoking reduces suicidality among individuals with psychosis: Complementary outcomes from a Healthy Lifestyles intervention study. *Psychiatry Res.* 243, 407-412.
 44. Cooperman NA, Lu SE, Richter KP, Bernstein SL, **Williams JM**. Influence of Psychiatric and Personality Disorders on Smoking Cessation Among Individuals in Opiate Dependence Treatment. *J Dual Diagn.* 2016 Apr 11:116-126. [Epub ahead of print]
 45. Lawrence D, **Williams JM**. Trends in Smoking Rates by Level of Psychological Distress-Time Series Analysis of US National Health Interview Survey Data 1997-2014. *Nicotine Tob Res.* 2016 Jun;18(6):1463-70. PMID: 26705303

46. **Williams JM**, Steinberg ML. Report ignores risk factor of tobacco in assessing suicidality. *J Clin Psychiatry*. 2015 Nov;76(11):1570-1. doi: 10.4088/JCP.151r10027.
47. Dickert J, **Williams JM**, Reeves R, Gara M and DeBilio L. Decreased Mortality Rates in Inmates with Mental Illness after a Tobacco-Free Prison Policy. *Psychiatr Serv*. 2015 Sep;66(9):975-9. doi: 10.1176/appi.ps.201400429. Epub 2015 May 15. PMID: 25975892
48. Steinberg ML, **Williams JM**, Li Y. Poor mental health and reduced decline in smoking prevalence. *Am J Prev Med*. 2015 Sep;49(3):362-9. doi: 10.1016/j.amepre.2015.01.016. Epub 2015 Jun 10. PMID:26071864
49. Steinberg ML, **Williams JM**, Stahl NF, Budsock PD, Cooperman NA. An adaptation of motivational interviewing increases quit attempts in smokers with serious mental illness. *Nicotine Tob Research*. 2015 Mar 5. pii: ntv043. [Epub ahead of print]
50. Steinberg ML, Stahl NF, **Williams JM**. Household smoking restrictions relate to time to first cigarette smoked in the morning. *J Smok Cessation*. Accepted, in Press
51. Baker AL, Richmond R, Kay-Lambkin FJ, Filia SL, Castle D, **Williams JM**, Lewin TJ, Clark V, Callister R, Weaver N. Randomised controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders. *Nicotine Tob Res*. 2015 Aug;17(8):946-54. doi: 10.1093/ntr/ntv039. Epub 2015 Mar 5.
52. Jasek JP, **Williams JM**, Mandel-Ricci J, Johns M. Trends in smoking among adults with serious psychological distress during comprehensive tobacco control in New York City, 2003-2012. *Tobacco Control*. doi:10.1136/tobaccocontrol-2014-052024
53. Cooperman NA, Richter KP, Bernstein SL, Steinberg ML & **Williams JM**. Determining smoking cessation related information, motivation, and behavioral skills among opiate dependent smokers in methadone treatment. *Subst Use Misuse*. 2015 Apr;50(5):566-81. doi: 10.3109/10826084.2014.991405. Epub 2015 Jan 5. PMID:25559697
54. **Williams JM**, Stroup S, Brunette MF, Raney L. Tobacco Use and Mental Illness: a Wake-up Call for Psychiatrists. *Psychiatric Services* 2014; doi: 10.1176/appi.ps.201400235
55. **Williams JM**, Miskimen T, Minsky S, Cooperman NA, Miller M, Dooley Budsock P, Cruz J and Steinberg ML. Increasing Tobacco Dependence Treatment through Continuing Education Training for Behavioral Health Professionals. *Psychiatric Serv*. 2015 Jan 1;66(1):21-6. doi: 10.1176/appi.ps.201300523. Epub 2014 Nov 17. PMID:25220158

56. **Williams JM**, Willett JG, Miller G. Partnership between tobacco control programs and offices of mental health needed to reduce smoking rates in the United States. *JAMA Psychiatry*. 2013 Dec;70(12):1261-2. doi: 10.1001/jamapsychiatry.2013.2182.
57. **Williams JM**, Steinberg ML, Griffiths KG and Cooperman N. The Need for Smokers with Behavioral Health Comorbidity to Be Designated as a Tobacco Use Disparity Group. *Am J Public Health*. 2013 Sep;103(9):1549-55. doi: 10.2105/AJPH.2013.301232. Epub 2013 Jul 18. PMID: 23865661
58. Tobia A, Draschil T, Sportelli D, Katsamanis M, Rosenberg S, **Williams JM**. The horror!: a creative framework for teaching psychopathology via metaphorical analyses of horror films. *Acad Psychiatry*. 2013 Mar 1;37(2):131-6.
59. Steinberg ML, **Williams JM**. State, but not trait measures of persistence are related to negative affect. *J Stud Alcohol Drugs*, 2013 Jul;74(4):584-8. PMID: 3739022
60. **Williams JM**, Gandhi KK, Lu SE, Steinberg ML and Benowitz NL. Nicotine Intake and Smoking Topography in Smokers with Bipolar Disorder. *Bipolar Disorders* 2012 Sep;14(6):618-27.
61. **Williams JM**, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C and George TP. A Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients with Schizophrenia or Schizoaffective Disorder. *J Clin Psychiatry* 2012 May; 73(5): 654-660.
62. **Williams JM**. Varenicline Should be Used as a First Line Treatment to Help Smokers with Mental Illness Quit. *Journal of Dual Diagnosis*, 8(2), 113–116, 2012.
63. Filia SL, Baker AL, Kulkarni J, **Williams JM**. Sequential behavioral treatment of smoking and weight control in bipolar disorder. *Translational Behavioral Medicine Transl Behav Med*. 2012 Sep;2(3):290-5. doi: 10.1007/s13142-012-0111-1. PMID: 24073127
64. Steinberg ML, **Williams JM**, Gandhi KK, Foulds J, Epstein EE, Brandon TH. Task Persistence Predicts Smoking Cessation in Smokers With and Without Schizophrenia. *Psychol Addict Behav*. 26(4):850-858, 2012
65. **Williams JM**, Gandhi KK, Lu SE, Steinberg ML, Benowitz NL. Rapid Smoking May not be Aversive in Schizophrenia. *Nicotine Tob Res*. 2012 Mar;14(3):377-82. Epub 2011 Aug 16. doi: 10.1093/ntr/ntr314
66. Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, **Williams J**, Murtaugh C, Montoya I, Yu E, Elkashef A. Selegiline Transdermal

System (STS) as an aid for smoking cessation, *Nicotine Tob Res* 2012 Mar;14(3):377-82. Epub 2011 Aug 16.

67. **Williams JM**, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J. Review of Varenicline for tobacco dependence: panacea or plight? *Expert Opin Pharmacother*, Aug;12(11):1799-812, 2011.
68. **Williams JM**, Gandhi KK, Lu SE, Kumar S, Steinberg ML, Cottler B, Benowitz NL. Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. *Drug Alcohol Depend*, 2011 Nov 1;118(2-3):313-9. Epub 2011 May 18.
69. Baker A, Kay-Lambkin FJ, Richmond R, Filia S, Castle D, **Williams J**, Lewin TJ. Study protocol: a randomised controlled trial investigating the effect of a healthy lifestyle intervention for people with severe mental disorders. *BMC Public Health*, 11(10), 1471-2458, 2011.
70. **Williams JM**, Zimmermann MH, Steinberg ML, Gandhi KK, Delnevo C, Steinberg MB, Foulds J. A comprehensive model for mental health tobacco recovery in New Jersey. *Adm Policy Mental Health*, Sep;38(5):368-83, 2011.
71. **Williams JM**, Dwyer M, Verna M, Zimmermann MH, Gandhi KK, Galazyn M, Szkodny N, Molnar, Kley R, Steinberg ML. Evaluation of the CHOICES program of peer-to-peer tobacco education and advocacy. *Community Ment Health, J* Jun;47(3):243-51, 2011.
72. Steinberg MB, Bover MT, Richardson DL, Schmelzer AC, **Williams JM**, Foulds J. Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. *Drug Alcohol Depend*, Mar 1;114(1):77-81, 2010.
73. Steinberg ML, **Williams JM**, Gandhi KK, Foulds J, Brandon TH. Lower task persistence in smokers with schizophrenia as compared to non-psychiatric control smokers. *Psychol Addict Behav*, Dec;24(4):724-9, 2010.
74. **Williams JM**, Gandhi KK, Benowitz NL. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. *Cancer Epidemiol Biomarkers Prev*, Oct;19(10):2582-9, 2010.
75. Galazyn M, Steinberg ML, Gandhi KK, Piper M, **Williams JM**. Reasons for smoking among individuals with schizophrenia. *Schizophr Res*, Sep;122(1-3):268-9, 2010.
76. **Williams JM**, Gandhi KK, Lu SE, Kumar S, Shen J, Foulds J, Kipen H, Benowitz NL. Higher nicotine levels in schizophrenia compared to controls after smoking a single cigarette. *Nicotine Tob Res*, Aug;12(8):855-9, 2010.

77. Gandhi KK, **Williams JM**, Menza M, Galazyn M, Benowitz, NL. Serum caffeine in smokers with schizophrenia compared to smoking controls. *Drug Alcohol Depend*, Jul 1;110(1-2):151-5, 2010.
78. **Williams JM**, Steinberg ML, Zimmermann MH, Gandhi KK, Stipelman B, Budsock PD, Ziedonis DM. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. *J Subst Abuse Treat*, Jun;38(4):384-93, 2010.
79. Steinberg ML, Heimlich L, **Williams JM**. Tobacco use among individuals with intellectual or developmental disabilities: A brief review. *Intellect Dev Disabil*, 47(3): 197–207, 2009.
80. **Williams JM**, Ziedonis DM, Vreeland B, Speelman-Edwards N, Zechner MR, Williams MT, Rahim R, Karimi L, Molnar M, Eilers R. A wellness approach to addressing tobacco in mental health settings: Learning about Healthy Living. *Am J Psychiatr Rehabil*, 12:352-369, 2009.
81. **Williams JM**, Steinberg ML, Hanos Zimmermann M, Gandhi KK, Lucas GE, Gonsalves DA, Pearlstein I, McCabe P, Galazyn M, Salsberg E. Training psychiatrists and advanced practice nurses to treat tobacco dependence. *J Am Psychiatr Nurses Assoc*, 159(1): 50-58, 2009.
82. Gandhi KK, Foulds J, Steinberg MB, Lu SE, **Williams JM**. Lower quit rates among menthol cigarette smokers at a specialist tobacco treatment clinic. *Int J Clin Prac*, 63, 3, 360–367, 2009.
83. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, **Williams J**, Calhoun PS, Riley WT. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine Tob Res*, Dec;10(12):1691-715, 2008.
84. **Williams JM**, Gandhi KK, Karavidas MK, Steinberg ML, Lu SE, Foulds J. Open label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch. *J Dual Diagn*, 4(4):355- 376, 2008.
85. **Williams JM**. Eliminating tobacco use in mental health facilities: Patients' rights, public health, and policy issues. *JAMA*, 299(5): 571-573, 2008.
86. **Williams JM** & Gandhi KK. Use of caffeine and nicotine in people with schizophrenia. *Curr Drug Abuse Rev*, 1(2): 155-161, 2008.
87. Hagman BT, Delnevo CD, Hrywna M, **Williams JM**. Tobacco use among those with serious psychological distress: findings from the National Survey of Drug Use and Health, 2002. *Addict Behav*, Apr;33(4):582-92, 2008.

88. Steinberg ML & **Williams JM**. Psychosocial treatments for individuals with schizophrenia and tobacco dependence. *J Dual Diagn*, 3(3/4): 99-112, 2007.
89. Tidey J & **Williams JM**. Clinical indices of tobacco use in people with schizophrenia. *J Dual Diagn*, 3(3/4): 79-98, 2007.
90. **Williams JM**. Using peer counselors to address tobacco: the CHOICES program. *Psychiatr Serv*, 58(9): 1225, 2007.
91. Vega WA, Chen KW, **Williams JM**. Smoking, drugs, and other behavioral health problems among multiethnic adolescents in the NHSDA. *Addict Behav*, Sep;32(9):1949-56, 2007.
92. **Williams JM**, Gandhi KK, Steinberg ML, Foulds J, Ziedonis DM, Benowitz NL. Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. *Nicotine Tob Res*, 9(8):873-81, 2007.
93. **Williams JM** & Foulds J. Successful tobacco dependence treatment in schizophrenia. *Am J Psychiatry*, 164(2): 222-227, 2007.
94. Ziedonis DM, Guydish J, **Williams JM**, Steinberg ML, Foulds J. Barriers and solutions to addressing tobacco dependence in addiction treatment programs. *Alcohol Res Health*, 29(3):228-35, 2006.
95. Foulds J, **Williams JM**, Order-Connors, Edwards N, Dwyer M, Kline A, Ziedonis DM. Integrating tobacco dependence treatment and tobacco-free standards into addiction treatment in New Jersey: lessons for other states. *Alcohol Res Health*, 29(3):236-40, 2006.
96. **Williams JM**, Cain BW, Fredericks T, O'Shaughnessy M. A tobacco treatment model for individuals with serious mental illness. *Psychiatr Serv*, 57(8): 1210, 2006.
97. Foulds J, **Williams JM**, Gandhi KK. Racial differences in lung cancer (Letter). *NEJM*, 354;18: 1951-1952, 2006.
98. **Williams JM** & Ziedonis DM. Snuffing out tobacco dependence: ten reasons behavioral health providers need to be involved. *Behav Healthc*, 26(5):27-30, 2006.
99. Ziedonis DM, **Williams JM**, Steinberg M, Foulds J. Addressing tobacco in office-based management of psychiatric disorders: practical considerations. *Prim Psychiatry*, 13(2): 51-63, 2006.
100. Smelson DA, Ziedonis D, Losonczy MF, **Williams J**, Steinberg ML, Kaune M. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with

schizophrenia and cocaine dependence: A preliminary report. *J Clin Psychopharmacol*, Feb;26(1):9-12, 2006.

101. Foulds J, Steinberg M, **Williams JM**, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. *Drug and Alcohol Review*, Jan;25(1):59-71, 2006.
102. Foulds J, Gandhi KK, Steinberg MB, Richardson D, **Williams JM**, Burke M, Rhoads GG. Factors associated with quitting smoking at a tobacco dependence treatment clinic. *Am J Health Behav*, 30(4):400-412, 2006.
103. **Williams JM**, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. *Schizophr Res*, 79(2-3):323-335, 2005.
104. Foulds J & **Williams JM**. Tobacco use and cataracts in patients with schizophrenia. *Am J Psychiatry*, May;162(5):1028, 2005.
105. **Williams JM**, Foulds J, Dwyer M, Order-Connors B, Springer M, Gadde P, Ziedonis DM. The integration of tobacco dependence treatment into residential addictions treatment in New Jersey. *J Subst Abuse Treat*, 28: 331– 340, 2005.
106. Steinberg ML, **Williams JM**, Steinberg HR, Krejci JA, Ziedonis DM. Applicability of the Fagerström Test for nicotine dependence in smokers with schizophrenia. *Addict Behav*, Jan;30(1):49-59, 2005.
107. **Williams JM**, Ziedonis DM, Foulds J. Case series of nicotine nasal spray in the combination treatment of tobacco dependence among patients with schizophrenia. *Psychiatr Serv*, 55(9): 1064-1066, 2004.
108. Foulds J, Burke M, Steinberg M, **Williams JM**, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. *Expert Opin Emerg Drugs*, 9(1):39-51, 2004.
109. Steinberg ML, **Williams JM**, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. *Tob Control*, Jun;13(2):206, 2004.
110. **Williams JM** & Ziedonis DM. Addressing tobacco among individuals with a mental illness or an addiction. *Addict Behav*, 29(6):1059-1270, 2004.
111. Ziedonis D, **Williams JM**, Smelson DA. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. *Am J Med Sci*, Oct;326(4):223-30, 2003.

112. **Williams JM** & Hughes JR. Pharmacotherapy treatments for tobacco dependence among smokers with mental illness or addiction. *Psychiatr Ann*, 22(7):457-466, 2003.
113. Ziedonis DM & **Williams JM**, Co-Editors of Issue. Addressing tobacco in mental health and addictions settings. *Psychiatr Ann*, 22(7), 2003.
114. Ziedonis DM & **Williams JM**. Management of smoking in people with psychiatric disorders. *Curr Opin Psychiatry*, 16(3): 305-315, 2003.
115. **Williams JM** & Ziedonis D. Naltrexone-bupropion combination therapy for protracted abstinence dysphoria. *Am J Addict*, 12(3):270-272, 2003
116. Ziedonis D & **Williams J**. When psychosis and substance use coincide in the emergency service. *Psychiatric Issues in Emergency Care Settings*, Summer; 3-13, 2002.
117. **Williams J** & Ziedonis D. Emergency management of psychosis and substance abuse. *Psychiatric Issues in Emergency Care Settings*, Summer; 14-19, 2002
118. Ziedonis D, **Williams J**, Corrigan P, Smelson D. Management of substance abuse in schizophrenia. *Psychiatr Ann*, 30(1):67-75, 2000.
119. **Williams J** & Swartz M. Treatment boundaries in the case management relationship: a clinical case and discussion. *Community Ment Health J*, (34)3: 299-311, 1998.
120. Menza MA, **Cocchiola-Williams J**, Golbe L. Psychiatric symptoms in Progressive Supranuclear Palsy. *Psychosomatics*, 36(6):550-554, 1995.

Books, Monographs, & Chapters

1. **Williams JM**, Cooperman N and Chaguturu V. Treatment of Tobacco-Related Disorders. In *The American Psychiatric Press Textbook of Substance Use Disorder Treatment*, Sixth Edition,. Editors Brady K, Levin F, Galanter M, Kleber HD. 2021
2. **Williams JM**, Delnevo C, & Ziedonis DM. The Unmet Needs of Smokers with Mental Illness or Addiction. In *After Tobacco: What Would Happen If Americans Stopped Smoking?* Bearman, Neckerman and Wright (Eds). Columbia University Press, 2011.
3. Vreeland B., Toto AM, Verna M. & **Williams JM**. Cultivating Physical Health and Wellness Utilizing a Person-Centered Approach. In *Serious Mental Illness (SMI): Person-centered Approaches* [Rudnick, A., & Roe D. Eds.] Radcliff Press, 2011.

4. Ziedonis DM, **Williams JM**, Steinberg ML, Smelson D, Sussner B, Foulds J, Krejci J, , Violette N. Addressing Tobacco Dependence Among Individuals with a Psychiatric Disorder: A Neglected Epidemic of Major Clinical and Public Health Concern. In Isaacs SL (Ed.) VA in the Vanguard: Building on Success in Smoking Cessation. Proceedings of Conference, San Francisco, September 21, 2004, Published 2005.
5. Osinubi Omowunmi, Barbeau Elizabeth, **Williams Jill M**, Sorensen Glorian. Curbing the Tobacco Epidemic: The Role of Workplace Tobacco Control Policies and Programs in Focus on Smoking and Health Research, Nova Science Publishers, pp 1-75, 2005.
6. **Williams J** and Eick C. Evaluating and Managing Patients Who are not Responding to Treatment. In Integrated Treatment for Mood and Substance Use Disorders. Eds. JJ Westermeyer, RD Weiss, DM Ziedonis. Johns Hopkins University Press, 140-160, 2003.

Other Articles in Journals, Chapters; Books; other Professional Communications

1. **Williams JM**, Steinberg ML and Willett J. Report ignores key issue in tobacco end game: smokers with behavioral health comorbidity. Tobacco Control online letters. June 11, 2013. <http://tobaccocontrol.bmj.com/letters>
2. **Williams J** and Verna M. Strong Advocacy Effort Needed to Help Smokers with Mental Illness. NAMI Advocate. Spring 2013.
<http://www.nami.org/template.cfm?Section=home%20&template=/ContentManagement/ContentDisplay.cfm&ContentID=152001&lstd=837>
3. **Williams, JM**. Director and Co-Writer, Smoke Alarm Video: The Truth about Smoking and Mental Illness. Produced by the Clubhouse of Suffolk from a grant from the NY State Department of Health, 2006.
4. **Williams JM**, Ziedonis D, Speelman N, Vreeland B, Zechner MR, Rahim R, O’Hea EL. Learning about Healthy Living: Tobacco and You Manual. State of New Jersey, Division of Mental Health Services, Revised June 2005.
5. **Williams JM**, Ziedonis DM, Krejci J, Steinberg ML. Tobacco Medication Management Treatment Manual. Treatment of Addiction to Nicotine in Schizophrenia Study (R01 DA015537). National Institute on Drug Abuse (NIDA), 2004.

Abstracts

1. Williams JM, Dooley-Budsock P, Mattern D, Kline A. Challenges to Stop Smoking in Individuals with Mental Illness. Presented at the Society of Research on Nicotine and Tobacco (SRNT), 30th Annual Meeting. Edinburgh, March 22, 2024.
2. Williams JM, Covell NH, Foster F, Lipton N. Self- Evaluation Tool to Support Implementation of Treatment for Tobacco in Behavioral Health. Poster Presentation at NCTOH. New Orleans. June 2022.
3. Williams JM, Syed MA, Adesanya A, Gardner G, Chaguturu V and Coppola K. RIOTing to Educate NJ About the Opioid Epidemic Poster presentation at NJ Division of Mental health and Addiction Services Opioid Summit Sept 21-22, 2021
4. Williams JM. Practice Change after Training Psychiatry Residents in Tobacco Use Disorder. Accepted for the 2020 Annual Meeting of the American Psychiatric Association. April 2020 (canceled due to COVID-19).
5. Turner A, Baker AL, Borland R, Bonevski B, Segan C, Brophy L, McCarter K, Kelly PJ, Williams JM, Baird D, Attia J, Sweeney R, White SL, Filia S, Castle D. Protocol for a randomised controlled trial of Quitlink: Peer Worker facilitated quitline support for smokers receiving mental health services. Society for Mental Health Research conference proceedings, 27-29 November 2019, Melbourne, Australia.
6. Williams JM, Lu SE, Gandhi KK, Steinberg ML. Initial Nicotine Nasal Spray Experience among Smokers with and without Schizophrenia. Presented at the 20th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA. February 2015.
7. Williams JM, Lu SE, Gandhi KK, Steinberg ML. Randomized, Double-Blind, Placebo Controlled Trial of Nicotine Nasal Spray for Smoking Cessation in Schizophrenia. Presented at the 20th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA. February 2015.
8. Williams JM, Miskimen T, Minsky S, Miller M, Cooperman N and Steinberg ML. Training Psychiatrists Results in Increased Tobacco Treatment. Presented at the 19th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Seattle, WA. February 2014, POS3-108.
9. Williams JM, Gandhi KK, Steinberg ML, Lu SE. Randomized Double-Blind Placebo-Controlled Trial of Nicotine Nasal Spray for Smoking Cessation in Schizophrenia. Presented at the 23rd Annual Meeting of the American Academy of Addiction Psychiatry, Miami, FL. December 2012.
10. Maher KH, Ziedonis DM, Williams JM and George TP. Tobacco Use and Cessation in Patients with Co-occurring Disorders. Symposium Presented at the

23rd Annual Meeting of the American Academy of Addiction Psychiatry, Miami, FL. December 2012

11. Williams JM, Gandhi KK, Lu SE and Benowitz. Increased Nicotine Metabolism and Shorter Interpuff Interval in Smokers with Bipolar Disorder. Presented at the 18th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Houston, Texas. March 2012.
12. Williams JM, Anthenelli RM, Morris C, Treadow J, Thompson JR, Yunis C and George TP. A Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Schizophrenia and Schizoaffective Disorder. Presented at the 18th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Houston, Texas. March 2012.
13. Williams JM, Gandhi KK, Kumar S, Cooperman N, Lu SE. Rapid Smoking may not be aversive to schizophrenia. Presented at the 17th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Toronto, Canada. February 2011, POS3-58, Page 102.
14. Williams JM, Gandhi KK, Kumar S, and Lu SE. Shorter interpuff interval associated with greater nicotine intake in smokers with and without schizophrenia. Presented at the 73rd Annual Meeting of the College on Problems of Drug Dependence, Hollywood, Florida, June 2011
15. Gandhi KK, Williams JM, Kumar S and Benowitz NL. Effects of smoking on caffeine intake among individuals with and without schizophrenia. Presented at the 73rd Annual Meeting of the College on Problems of Drug Dependence, Hollywood, Florida, June 2011
16. Cooperman NA, Williams JM, Richter KP, Bernstein SL. Client and clinician perspectives on developing a tailored smoking cessation intervention for methadone maintained smokers. Presented at the 17th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Toronto, Canada. February 2011, POS5-66, page 150.
17. Williams JM, Gandhi KK, Lu SE, Foulds J, Shen J, Kumar S and Benowitz N. Higher and Earlier Nicotine Peak in Smokers with Schizophrenia, Presented at 16th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD, February 2010.
18. Kumar S, Gandhi KK, Williams JM, Galazyn M, Echeverria S, Steinberg M and Foulds J. The Role of Social Deprivation Factors on Nicotine Intake. Presented at the Joint Conference of SRNT and SRNT-Europe, Dublin, Ireland, April 2009.
19. Williams JM, Steinberg ML, Zimmermann MH, Gandhi KK, Stipleman B, Dooley T and Ziedonis DM. Comparison of Two Smoking Cessation Behavioral

- Therapies Combined with Nicotine Patch in Schizophrenia. Presented at Joint Conference of SRNT and SRNT-Europe, Dublin, Ireland, April 2009.
20. Williams JM, Gandhi KK, Galazyn M, Kumar S, Hill S, Carmella SG and Hecht SS. Carcinogen Biomarkers in Smokers with Schizophrenia. Presented at 2009 Joint Conference of SRNT and SRNT-Europe, Dublin, Ireland, April 2009.
 21. Gandhi KK, Williams JM, Galazyn M, Kumar S, Steinberg ML and Benowitz M. Smoking Characteristics and Nicotine Intake in Individuals with Bipolar Disorder. Presented at Joint Conference of SRNT and SRNT-Europe, Dublin, Ireland, April 2009.
 22. Williams JM, Gandhi KK, Lucas GE, Gonsalves DA, Zimmermann M, Galazyn M, Steinberg ML. Training Psychiatrists and Mental Health Professionals to Treat Tobacco Dependence. Presented at the 14th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Portland, OR. February 2008.
 23. Gandhi KK, Williams JM, Galazyn M, Benowitz. Higher Serum Caffeine in Smokers with Schizophrenia as Compared to Controls. Presented at 14th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT). Portland, OR, February 2008.
 24. Galazyn M, Steinberg ML, Gandhi KK, Piper M, Williams JM. Reasons for Smoking among Individuals with Schizophrenia. Presented at 14th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT). Portland, OR, February 2008.
 25. Williams JM. Using Peer Counselors To Address Tobacco: The CHOICES Program. Presented at National Conference on Tobacco or Health, Minneapolis, MN, October 2007.
 26. Williams JM, Gandhi KK, Karavidas M, Steinberg ML, Galazyn M, Foulds J. Less craving in Abstinent Smokers with Schizophrenia using Nicotine Nasal Spray compared to those using Nicotine Patch. Presented at 13th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Austin, TX, February 2007.
 27. Williams JM, Gandhi KK, Karavidas M and Foulds J. More Puffs and Shorter Interpuff Interval in Smokers with Schizophrenia using CReSSmicro® Topography Device. Presented at 12th Annual Meeting of the Society for Research on Nicotine & Tobacco (SRNT), Orlando, FL, February 2006.
 28. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, and Benowitz N. Increased Nicotine and Cotinine Levels in Smokers with Schizophrenia and Schizoaffective Disorder is not a Metabolic Effect. Presented at 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Phoenix, AZ,

February 2004.

29. Williams JM, Foulds J, Dwyer M, Order-Connors B, Springer M, Gadde P, Ziedonis DM. The Integration of Tobacco Dependence Treatment into Residential Substance Abuse Treatment in New Jersey. Presented at 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Phoenix, AZ, February 2004.
30. Williams JM, Ziedonis D. A pilot feasibility study of high-dose patch for patients with schizophrenia. Presented at 9th Annual Meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA, February 2003.
31. Martha Dwyer, Jill Williams, et al. Integration of Tobacco Dependence into Residential Substance Abuse Treatment: Survey Results. Presented at 2003 National Conference on Tobacco or Health, Boston, MA, December 2003.
32. Smelson D, Williams J, Kaune M, Losonczy M, Menza M, Ziedonis D. Reduced cue-elicited cocaine craving and relapses following treatment with risperadone. Presented at American Psychiatric Association Annual Meeting, May 2000.
33. Williams J, Smelson D, Ziedonis D, Losonczy M. The efficacy of olanzepine in decreasing cue-elicited craving and relapse in withdrawn cocaine dependent schizophrenics. Presented at American Psychiatric Association's Research Colloquium for Junior Investigators, May 1999.
34. Williams J and Stein R. Dual diagnosis patients in a state facility: a comparison of staff attitudes with actual treatment practices. Presented at N.C. Governor's Institute for Alcohol and Substance Abuse, Public Policy Scholars Forum. N.C. State Legislature May 1996.

PRESENTATIONS:

Updates in Tobacco Recovery in SUD Treatment. Invited Keynote Speaker. BH Well Fall Conference. University of Kentucky. November 8, 2023.

Tobacco Use Disorder Pharmacotherapy: an Underused Arsenal. Invited Speaker. Presented at the Advanced Addiction Psychopharmacology Virtual Course. American Academy of Addiction Psychiatry. October 21, 2023.

Tobacco and Nicotine. Invited Speaker. Presented at the Addictions and Their Treatment Virtual Course. American Academy of Addiction Psychiatry. September 22, 2023.

Updates in Tobacco Recovery in SUD Treatment. Invited Keynote Speaker. 2nd Annual PA STFRI "Tobacco-Free Recovery Is Recovery" Statewide Conference. October 6, 2022

Tobacco. Invited Speaker. Presented at the Addictions and Their Treatment Virtual Course. American Academy of Addiction Psychiatry. September 30, 2022.

Nicotine and Tobacco Dependence. Invited Speaker. Presented at the Advanced Pharmacology of Addictions Virtual Course. American Academy of Addiction Psychiatry. October 29, 2022

Integrating Treatment into Behavioral Health. Invited speaker at 29th Annual Nicotine Dependence Center Conference. Mayo Clinic (Virtual) March 29, 2022

Updates in Tobacco Use Disorder Treatment. Invited speaker at 2022 Nevada Psychiatric Association Psychopharmacology Update. Feb 15, 2022

Tobacco Use Disorder Treatment Updates- Addictions 2021 Conference. Harvard Medical School CME, May 15, 2021

Updates in Tobacco Use Disorder Treatment. Howard University Fellows in Addiction Medicine. Virtual Session. January 5, 2021.

Tobacco Treatment and Recovery in Behavioral Health. Key Note Speaker- Kansas Health Foundation. Dec 12, 2020

Updates in the Treatment of Tobacco Use Disorder. Invited Speaker. Advanced Addiction Psychopharmacology Virtual Course. American Academy of Addiction Psychiatry. November 7, 2020.

Updates in the Treatment of Tobacco Use Disorder. Keynote Speaker. 2020 Addiction Medicine Essentials Conference. North Carolina Governor's Institute. October 16, 2020.

Tobacco. Invited Speaker. Presented at the Addictions and Their Treatment Virtual Course. American Academy of Addiction Psychiatry. October 3, 2020.

Grand Rounds- Updates in Tobacco Treatment- Interfaith Hospital – Sept 15, 2020. Brooklyn, NY

Grand Rounds- Updates in Tobacco Treatment- Brookdale Hospital – Sept 30, 2020. Brooklyn, NY

Tobacco Use Disorder. Invited Speaker. ASAM Board Exam Study Course. July 16, 2020

SMI Advisor- National Webinar Sponsored by SAMHSA and the APA. Updates in Treating Tobacco Use Disorder. May 15, 2020

Grand Rounds. Medication Assisted Treatment for Opioid Use Disorder. EOHSI Faculty and Staff, Rutgers University. April 17, 2020.

Grand Rounds. Medication Assisted Treatment for Opioid Use Disorder. Princeton Medical Center. January 14, 2020.

Tobacco. Invited Speaker. Presented at the Addictions and Their Treatment Course. American Academy of Addiction Psychiatry 30th Annual Meeting and Scientific Symposium. San Diego. Dec 2019.

Updates in the treatment of Tobacco Use Disorder. Invited Speaker. Advanced Addiction Psychopharmacology Course. American Academy of Addiction Psychiatry 29th Annual Meeting and Scientific Symposium. San Diego. Dec 2019.

Symposium at 2019 IPS: The Mental Health Services Conference. The Deadliest Drug Epidemic: How Psychiatrists and the Media Miss the Boat on Tobacco Addiction, and What to Do About It. New York City, Oct 4, 2019

Invited Speaker for NAMI Ask the Expert Webinar: With CHOICES and Support, You Can Quit Smoking. Nov 21, 2019

Challenges and Future Directions for Addressing Tobacco Use in Behavioral Health Settings. Invited Keynote Speaker. NYS Behavioral Health Tobacco Summit: Recognizing Success-Restoring Urgency. New York City. May 16, 2019

Online Residency Training in Tobacco Use Disorder. Paper session at American Academy of Addiction Psychiatry 29th Annual Meeting and Scientific Symposium. Bonita Springs, FL. Dec 2018.

Tobacco. Invited Speaker. Presented at the Addictions and Their Treatment Course. American Academy of Addiction Psychiatry 29th Annual Meeting and Scientific Symposium. Bonita Springs, FL. Dec 2018.

Updates in the treatment of Tobacco Use Disorder. Invited Speaker. Advanced Addiction Psychopharmacology Course. American Academy of Addiction Psychiatry 29th Annual Meeting and Scientific Symposium. Bonita Springs, FL. Dec 2018.

Invited Panelist and Speaker- Interagency Committee on Smoking and Health on Behavioral Health and Tobacco Control. Attended by Surgeon General, Vice Admiral Jerome M Adams, MD, MPH, and representatives from CDC, USDHHS, SAMHSA, FDA, NIH. June 14, 2018.

Addressing Tobacco in Individuals with a Behavioral Health Condition. Invited Lecture at Hazelden Betty Ford Foundation. Minneapolis, Minnesota. June 6, 2018

Invited Webinar Panelist- Truth Initiative Warner Series on Tobacco as a Social Justice Issue. Legacy Foundation DC. April 26, 2017

Changing Behavioral Health Systems to Treat Tobacco through Training and Policy Initiatives. Symposium presented at National Conference on Tobacco or Health. Austin, TX. March 2017

Changing Behavioral Health Systems to Treat Tobacco through Training and Policy Initiatives. Symposium Chair and Presenter. Presented at the 169th American Psychiatric Association Annual Meeting, Atlanta, Georgia. May 2016.

An Argument for Change in Tobacco Treatment Options Guided by the ASAM Criteria for Patient Placement. Presented at the American Psychiatric Association IPS Mental Health Services Conference. Annual Meeting, Washington, DC. October 2016.
Pre-conference Workshop on Tobacco Use Comorbidities. Presented at the 20th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA. February 2015.

Smoking and Mental Illness: A Wake Up Call for Psychiatrists. Featured Lecture. Oct 30, 2014. American Psychiatric Association, 66th Institute on Psychiatric Services. San Francisco, CA

Addressing Tobacco in NJ Youth & Families. Keynote Speaker- New Jersey's Fifth Statewide Conference on Children's Mental Health , October 28, 2014.

The Hidden Epidemic: Tobacco Use, Mental Illness and Substance Abuse. Keynote Speaker-Breathe Easy NC Tobacco-Free Living in the Behavioral Health Community Conference. June 2, 2014.

Research Update on Best and Promising Practices. Keynote Speaker- National Conference on Tobacco and Behavioral Health, Washington, DC. May 19, 2014.

Smoking, Mental Illness and Other Addictions: A Biopsychosocial Understanding of CoMorbidity. Keynote Speaker- Maine Intensive Tobacco Treatment Training and Conference. May 15, 2014

The Need for Addressing Tobacco in Behavioral Health. Keynote Speaker, North Dakota Behavioral Health Conference. May 12, 2014

Training Behavioral Health Professionals Increases Tobacco Dependence Treatment. Symposium Chairperson and Presenter. At 22nd National Institute of

Mental Health (NIMH) Conference on Mental Health Services Research (MHSR). April 23-25, 2014, Bethesda, MD.

Helping Smokers with Behavioral Health Comorbidity Requires a National Effort. Mind the Gap NIH Seminar Series, Bridging the Gap Between Evidence and Practice. April 16, 2013. Archived webcast at <http://videocast.nih.gov/PastEvents.asp>

Understanding High Nicotine Intake in Schizophrenia. Improving Smoking Cessation Treatment for People with Schizophrenia Meeting at NIH (NIDA, NIMH and NCI). April 3-4, 2013.

Tobacco and Other Substance Abuse. Research to Improve the Health and Longevity of People with Severe Mental Illness Meeting at NIMH. September 10-11, 2012

Smoking, Mental Illness and Other Addictions: A Biopsychosocial Understanding of CoMorbidity. Keynote Speaker- Mayo Clinic Annual Nicotine Dependence Conference. May 2012.

Updates in Smoking and Schizophrenia. National Webinar for Smoking Cessation Leadership Center. June 2011.

Treating Smokers with Mental Illness. Webinar for New York State Collaborative Of State Quitline and Cessation Centers. June 2011.

Tobacco Dependence Treatment in People with Serious Mental Illness. Grand Rounds Telecast to State Psychiatric Hospitals. NY State Office of Mental Health. May 2011.

Updates in Treating Tobacco Dependence in Mental Health Settings. Grand Rounds at Princeton House Behavioral Health Services. Princeton, NJ. March 2011.

Updates in Treating Tobacco Dependence in Mental Health Settings. Grand Rounds at Essex County Psychiatric Hospital. NJ November 2010.

Treating Tobacco Dependence in Mental Health Settings Half-Day Course, 62nd APA Institute on Psychiatric Services, Boston, MA, October 2010.

Updates in Treating Tobacco Dependence in Mental Health Settings. Grand Rounds at Holy Name Hospital Teaneck, NJ October 2010.

Current Clinical Concepts in Tobacco Treatment of Patients with Mental Illness. National Webinar and Grand Rounds at West Virginia University May 2010.

Updates in Treating Tobacco Dependence in Mental Health Settings. Grand Rounds at Lenox Hill Hospital Department of Psychiatry. NY December 2009.

Symposium. Smokers with Serious Mental Illness: A Focus on Mechanisms and Models, Joint Conference of SRNT and SRNT-Europe, Dublin, Ireland, April 2009.

Pharmacotherapy Treatments for Tobacco Dependence in Smokers with Mental illness. Grand Rounds at Cooper Hospital Department of Psychiatry. December 2009.

Pharmacology and Physiology of Addictions. Rutgers University Continuing Professional Education Full-day Seminars. February 2009 and 2010.

Using Policy and Systems Change to Address Tobacco in Mental Health or Addictions Treatment. Panel Presenter at the National Conference on Tobacco or Health. Phoenix 2009

The Unmet Needs of Smokers with Mental Illness or Addiction. Panel Presenter at the National Conference on Tobacco or Health. Phoenix 2009

Treating Tobacco in Mental Health Settings. Keynote Speaker at Annual Meeting of South Carolina Psychiatric Association. October 2008.

The Unmet Needs of Smokers with Mental Illness or Addiction, SAMHSA In-Service Training on Smoking Cessation and People with Behavioral Health Issues, Rockville, MD, July 2008.

Treating Tobacco in Mental Health Settings. New Jersey Psychiatric Association (NJPA) Spring Meeting. Woodbridge NJ, April 2008.

Maximizing The Power Of Partnerships: Engaging Smokers In The Mental Health Community at National Conference on Tobacco or Health, Minneapolis, MN, October 2007.

Addressing Tobacco Dependence and Mental Illness with the CHOICES Program, Annual Meeting of Mental Health America: Bringing Wellness Home, Washington, DC, June 2007.

Using Peer Counselors To Address Tobacco: The CHOICES Program, 59th Institute on Psychiatric Services as an Innovative Program. New Orleans, LA, October 2007.

No Advantage for High Dose Compared to Regular Dose Nicotine Patch on Short-term Abstinence Rates in Schizophrenia, 13th Annual Meeting of the

Society for Research on Nicotine and Tobacco (SRNT), Austin, TX, February 2007.

Addressing Tobacco in Mental health Settings, Colloquium Series on Research in Psychiatric Rehabilitation. NJ School of Health Related Professions. February 2007.

CHOICES, Public Education Institute of Mental Health America: Building a Culture of Mental Wellness, Austin, TX, January 2007.

Nicotine Dependence and Schizophrenia: Neurobehavioral Pathways, 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

The Consequences of Smoking: Why Address Tobacco in Mental Health? At Achieving Complete Wellness Through Transformational Partnerships: Helping Consumers Choose Healthier Lifestyles, University Behavioral Health Care, October 2006 & March 2007.

Using Peer Counselors To Address Tobacco: The CHOICES Program, Annual Conference of the NJ Psychiatric Rehabilitation Association, Edison, NJ, November 2006.

Impact of Menthol and Other Brand Characteristics on Blood Nicotine in Smokers with Schizophrenia versus Controls. Oral Paper Session at the 12th Annual Meeting of the Society for Research on Nicotine & Tobacco (SRNT), Orlando, FL, February 2006.

NIMH workgroup report on tobacco use and cessation in psychiatric disorders, 12th Annual Meeting of the Society for Research on Nicotine & Tobacco (SRNT). Orlando, FL, February 2006.

APA Forum Co-Chairperson, Should Psychiatrists and Other Mental Health Professionals Take a Lead in Tobacco Dependence Treatment, 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 2005.

Keynote Speaker, International Seminar on Smoking & Psychiatric Pathology. Satellite Seminar of the IV National Conference of S.E.D.E.T. (Spanish Society of Tobacco Dependence Specialists). Santander, Spain, May 2005.

Psychiatrists Should Take a Lead in Treating Tobacco, 15th Annual Meeting of American Academy of Addiction Psychiatry, San Juan, Puerto Rico, December 2004.

Treating Tobacco Dependence in Mental Health Settings, 2nd Annual University Behavioral HealthCare Best Practices, Best Outcomes Conference, Piscataway, NJ, October 2004.

Symposium Co-Chairperson, Practical Techniques in the Assessment and Treatment of Tobacco Dependence, 157th Annual Meeting of the American Psychiatric Association, New York, May 2004.

Tobacco Use with Mentally Ill and Addicted Populations, 10th Annual Meeting of the Society for Research on Nicotine and Tobacco, Phoenix, AZ, February 2004.

Keynote Speaker, Addressing Tobacco in Mental Health and Addictions Settings. Bridging the Gap Conference. Annual Conference of the UMDNJ-Division of Addiction Psychiatry, Piscataway, NJ, January 2004.

Treating Nicotine Dependence in Smokers with Mental Illness and Chemical Dependencies. National Conference on Tobacco or Health, Boston, MA, December 2003.

A Model Consultative Service for Addressing Tobacco in Mental Health, National Conference on Tobacco or Health. Boston, MA, December 2003.

Keynote Speaker, Nicotine Dependence and Psychiatric Co-Morbidity - A Clinical Approach to Nicotine Dependence Program of Suffolk County, Suffolk Co Department of Health Services, New York, October 2003.

Keynote Speaker, Tobacco, Mental Health and Stigma, Annual Conference of the UMDNJ-Tobacco Dependence Program, New Brunswick, NJ, September 2005.